Company
Enshorx
Targeting inflammatory bowel disease one patient at a time
Also known as Ensho Therapeutics, Ensho Therapeutics, Inc.
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
Claim, correct or request removal
Record updated 23 October 2026
About
Ensho Therapeutics, Inc., is a privately held, clinical-stage biopharmaceutical company focused on developing breakthrough oral therapies for patients with inflammatory diseases.
Funding snapshot
- Total raised
- $27.9MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Undisclosed, $7.3M2026-10-02
Funding rounds
- Round, 2026
- $7.3M2026-10-02, SEC form D sold
- Round, 2026
- 2026-01-209 investors
- Round, 2025
- $22.5M2025-06-12, SEC form D sold, 2 investors
- Round, 2024
- $5M2024-10-24, SEC form D sold, 1 investor
- Round, 2024
- $400K2024-07-19, SEC form D sold, 2 investors
Products
- Other
- NSHO-101
Loading relationship preview